An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
There are now 9 available FDA-approved second-generation long-acting injectable antipsychotics including aripiprazole (3), olanzapine (1), paliperidone (3), and risperidone (2). These high-cost medications are commonly used with the goal of improving adherence and patient outcomes. With almost 2 dec...
Saved in:
Main Author: | Amy M. VandenBerg, PharmD, BCPP (Author) |
---|---|
Format: | Book |
Published: |
American Association of Psychiatric Pharmacists,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Response to comment on the recently published article "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"
by: VandenBerg Amy M. PharmD, BCPP
Published: (2023) -
Comment on "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"
by: Still Daniel PharmD, BCPP, et al.
Published: (2023) -
Comparison of long-acting injectable antipsychotics with oral antipsychotics and hospital readmission rates in pediatric patients
by: Danial Chowdhury, PharmD, et al.
Published: (2024) -
Assessment of oral overlap with antipsychotic long-acting injectables initiated in an inpatient setting
by: Tran Jennifer T. PharmD, et al.
Published: (2023) -
Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners
by: Shaina Schwartz, PharmD, BCPP, et al.
Published: (2023)